Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19
Copyright © 2021 by the American Society of Nephrology..
Background: Patients with CKD ha ve impaired immunity, increased risk of infection-related mortality, and worsened COVID-19 outcomes. However, data comparing nondialysis CKD and ESKD are sparse.
Methods: Patients with COVID-19 admitted to three hospitals in the New York area, between March 2 and August 27, 2020, were retrospectively studied using electronic health records. Patients were classified as those without CKD, those with nondialysis CKD, and those with ESKD, with outcomes including hospital mortality, ICU admission, and mortality rates.
Results: Of 3905 patients, 588 (15%) had nondialysis CKD and 128 (3%) had ESKD. The nondialysis CKD and ESKD groups had a greater prevalence of comorbidities and higher admission D-dimer levels, whereas patients with ESKD had lower C-reactive protein levels at admission. ICU admission rates were similar across all three groups (23%-25%). The overall, unadjusted hospital mortality was 25%, and the mortality was 24% for those without CKD, 34% for those with nondialysis CKD, and 27% for those with ESKD. Among patients in the ICU, mortality was 56%, 64%, and 56%, respectively. Although patients with nondialysis CKD had higher odds of overall mortality versus those without CKD in univariate analysis (OR, 1.58; 95% CI, 1.31 to 1.91), this was no longer significant in fully adjusted models (OR, 1.11; 95% CI, 0.88 to 1.40). Also, ESKD status did not associate with a higher risk of mortality compared with non-CKD in adjusted analyses, but did have reduced mortality when compared with nondialysis CKD (OR, 0.57; 95% CI, 0.33 to 0.95). Mortality rates declined precipitously after the first 2 months of the pandemic, from 26% to 14%, which was reflected in all three subgroups.
Conclusions: In a diverse cohort of patients with COVID-19, we observed higher crude mortality rates for patients with nondialysis CKD and, to a lesser extent, ESKD, which were not significant after risk adjustment. Moreover, patients with ESKD appear to have better outcom es than those with nondialysis CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Kidney360 - 2(2021), 7 vom: 29. Juli, Seite 1107-1114 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khatri, Minesh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CKD |
|---|
| Anmerkungen: |
Date Completed 07.04.2022 Date Revised 05.04.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.34067/KID.0006852020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338982345 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338982345 | ||
| 003 | DE-627 | ||
| 005 | 20240405232936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.34067/KID.0006852020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM338982345 | ||
| 035 | |a (NLM)35368350 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khatri, Minesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes among Hospitalized Chronic Kidney Disease Patients with COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.04.2022 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by the American Society of Nephrology. | ||
| 520 | |a Background: Patients with CKD ha ve impaired immunity, increased risk of infection-related mortality, and worsened COVID-19 outcomes. However, data comparing nondialysis CKD and ESKD are sparse | ||
| 520 | |a Methods: Patients with COVID-19 admitted to three hospitals in the New York area, between March 2 and August 27, 2020, were retrospectively studied using electronic health records. Patients were classified as those without CKD, those with nondialysis CKD, and those with ESKD, with outcomes including hospital mortality, ICU admission, and mortality rates | ||
| 520 | |a Results: Of 3905 patients, 588 (15%) had nondialysis CKD and 128 (3%) had ESKD. The nondialysis CKD and ESKD groups had a greater prevalence of comorbidities and higher admission D-dimer levels, whereas patients with ESKD had lower C-reactive protein levels at admission. ICU admission rates were similar across all three groups (23%-25%). The overall, unadjusted hospital mortality was 25%, and the mortality was 24% for those without CKD, 34% for those with nondialysis CKD, and 27% for those with ESKD. Among patients in the ICU, mortality was 56%, 64%, and 56%, respectively. Although patients with nondialysis CKD had higher odds of overall mortality versus those without CKD in univariate analysis (OR, 1.58; 95% CI, 1.31 to 1.91), this was no longer significant in fully adjusted models (OR, 1.11; 95% CI, 0.88 to 1.40). Also, ESKD status did not associate with a higher risk of mortality compared with non-CKD in adjusted analyses, but did have reduced mortality when compared with nondialysis CKD (OR, 0.57; 95% CI, 0.33 to 0.95). Mortality rates declined precipitously after the first 2 months of the pandemic, from 26% to 14%, which was reflected in all three subgroups | ||
| 520 | |a Conclusions: In a diverse cohort of patients with COVID-19, we observed higher crude mortality rates for patients with nondialysis CKD and, to a lesser extent, ESKD, which were not significant after risk adjustment. Moreover, patients with ESKD appear to have better outcom es than those with nondialysis CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CKD | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a chronic kidney disease | |
| 650 | 4 | |a dialysis | |
| 650 | 4 | |a end stage renal disease | |
| 650 | 4 | |a mortality | |
| 700 | 1 | |a Charytan, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Parnia, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Petrilli, Christopher M |e verfasserin |4 aut | |
| 700 | 1 | |a Michael, Jeffrey |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, David |e verfasserin |4 aut | |
| 700 | 1 | |a Tatapudi, Vasishta |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Benstein, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Horwitz, Leora I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney360 |d 2020 |g 2(2021), 7 vom: 29. Juli, Seite 1107-1114 |w (DE-627)NLM311083633 |x 2641-7650 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2021 |g number:7 |g day:29 |g month:07 |g pages:1107-1114 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.34067/KID.0006852020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2021 |e 7 |b 29 |c 07 |h 1107-1114 | ||